Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05592626 · ClinicalTrials.gov registry record · Phase 1

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

A Phase 1 study of Neoplasms and Advanced Solid Tumors, sponsored by Marengo Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
365
Enrollment target
20
Study locations

NCT05592626 is a Phase 1 study of Neoplasms and Advanced Solid Tumors that is actively recruiting participants, run by Marengo Therapeutics. The registered enrollment target is 365 participants, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05592626, a Phase 1 study of Neoplasms and Advanced Solid Tumors, is actively recruiting participants, sponsored by Marengo Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
365 participants
Enrollment target
20
Study locations

Study Summary

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.

Conditions Studied

Neoplasms Advanced Solid Tumors Carcinoma Neoplasms by Site Urogenital Neoplasms Lung Neoplasm Epstein-Barr Virus Infections Papillomavirus Infection Genital Neoplasm, Female Vulvar Neoplasms

Interventions

  • DRUG STAR0602

Study Locations (20)

California

  • Loma Linda University Cancer Center - Loma Linda
  • UC Davis Comprehensive Cancer Center - Sacramento

Florida

  • AdventHealth Celebration - Celebration
  • University of Miami Sylvester Comprehensive Cancer Center - Miami

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Dana-Farber Cancer Institute - Boston

Texas

  • The University of Texas, MD Anderson Cancer Center - Houston
  • UT Health Mays Cancer Center - San Antonio

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Kansas

  • The University of Kansas Cancer Center - Kansas City

Maryland

  • National Institutes of Health - Bethesda

Michigan

  • Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 365 participants
Start Date 2023-01-04
Est. Completion 2026-10
Phase Phase 1

Sponsor

Marengo Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05592626

The ClinicalTrials.gov registry entry for NCT05592626 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (77% lower). The listed sponsor is Marengo Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which STAR0602 is the first listed.

NCT05592626 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05592626 about?

NCT05592626 is a clinical study titled "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors". This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.

What is the current status of trial NCT05592626?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 365 participants. The study started on 2023-01-04. Estimated completion is 2026-10.

What conditions does trial NCT05592626 study?

This clinical trial studies the following conditions: Neoplasms, Advanced Solid Tumors, Carcinoma, Neoplasms by Site, Urogenital Neoplasms.

What interventions are being tested in trial NCT05592626?

The interventions under investigation include: STAR0602 (DRUG).

Who is sponsoring clinical trial NCT05592626?

This trial is sponsored by Marengo Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05592626 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.